Company intelligence / Profile preview

MycRx

Melbourne, Victoria, Australiamycrxpharma.com ↗

Ownership: Private
Employees: ~14
Development stage: Preclinical

Overview

MycRx compounds display potent cellular Myc target engagement driving profound transcriptional inhibition and on-target mechanistic profiles, resulting in compelling anti-cancer activity. The company has built a comprehensive dataset optimizing existing late lead compounds to candidate selection with potent and selective activity, good PK properties in rodents, including oral bioavailability[3][4].

Therapeutic areas: Oncology
Modalities: Small molecule inhibitors
Industry: Biotech

Drug pipeline

1 asset

MRX-5287

Preclinical

Partnerships

CSIROPeter MacCallum Cancer Centre (PMCC)[4]

Beyond the preview

Go deeper on MycRx.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MycRx.

Explore the full profile